TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno GmbH was previously owned by Bristol Myers Squibb. Financial terms have not been disclosed. The acquisition expands TQx’s access to
read more
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal hyperexcitability disorders, to advance SiteOne’s leading asset STC-004. Lilly will lead STC-004 through phase 2 trials and
read moreAlnylam Pharmaceuticals has put its dancing shoes on to raise awareness of the experience of living with acute hepatic porphyria. More: Alnylam’s new Givlaari campaign choreographed by dancer living with rare disease Source: fierce
read moreNovartis was locked in a heated bidding war with another interested party for weeks before Regulus accepted Novartis’ final offer in late April, a new filing shows. More: Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster,
read moreWhile the Trump administration’s threat of pharmaceutical import tariffs and most favored nation drug pricing has weighed heavily on the pharmaceutical industry in recent months, many branded drugmakers are well-positioned to handle the pressures, S&P Global said in a new
read moreA month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme, the developer of the treatment, Scynexis, has resumed a phase 3 study, dosing its first new patient. The trial resumption triggers a $10 million
read more© 1994 - 2026 B.M. Pharmaceuticals